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Background/Aims: We investigated the frequency of occult hepatitis B virus (HBV) infection in anti-hepatitis C virus 
(HCV)-positive individuals and the effects of occult HBV infection on the severity of liver disease. Methods: Seventy-one 
hepatitis B virus surface-antigen (HBsAg)-negative patients were divided according to their HBV serological status into groups A 
(anti-HBc positive, anti-HBs negative; n=18), B (anti-HBc positive, anti-HBs positive; n=34), and C (anti-HBc negative, anti-HBs 
positive/negative; n=19), and by anti-HCV positivity (anti-HCV positive; n=32 vs. anti-HCV negative; n=39). Liver biopsy samples 
were taken, and HBV DNA was quantified by real-time PCR. Results: Intrahepatic HBV DNA was detected in 32.4% (23/71) of 
the entire cohort, and HBV DNA levels were invariably low in the different groups. Occult HBV infection was detected more 
frequently in the anti-HBc-positive patients. Intrahepatic HBV DNA was detected in 28.1% (9/32) of the anti-HCV-positive and 
35.9% (14/39) of the anti-HCV-negative subjects. The HCV genotype did not affect the detection rate of intrahepatic HBV DNA. 
In anti-HCV-positive cases, occult HBV infection did not affect liver disease severity. Conclusions: Low levels of intrahepatic 
HBV DNA were detected frequently in both HBsAg-negative and anti-HCV-positive cases. However, the frequency of occult HBV 
infection was not affected by the presence of hepatitis C, and occult HBV infection did not have a significant effect on the disease 
severity of hepatitis C. (Korean J Hepatol 2011;17:206-212)
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INTRODUCTION
Occult hepatitis B virus (HBV) infection is defined as the 
presence of low HBV DNA levels in the blood, liver tissue, or 
peripheral monocytes of hepatitis B surface antigen (HBsAg)- 
negative persons.
1,2 It has been reported that in individuals with 
occult HBV infection, the DNA level in peripheral blood is 
usually fewer than 10
3 copies/mL and as low as 1,000 copies per 
1 µg of DNA extracted from liver tissue.
3-5 Advances in detection 
technologies in the past decade have allowed greater insight into 
occult HBV infection.
Occult HBV infection is divided into seropositive (anti-HBc 
(IgG) positive), and seronegative (anti-HBc (IgG) negative) 
cases. It has been reported that the rate of occult infection is 
higher in seropositive cases. Additionally, the rate of occult HBV 
infection is higher in areas of high HBV prevalence
6 and in those 
with hepatitis C virus (HCV) or human immunodeficiency virus 
(HIV) infection.
7-9 Recent data showed that occult HBV 
infection was detected in 37 (41.6%) of the 89 patients with 
biopsy proven chronic hepatitis C.
10 However, reported 
frequencies of occult infection vary considerably, probably due 
to a lack of standardized diagnostic protocols; this results in 
different diagnoses being obtained from similar or identical 
samples. Jae Young Jang, et al. Occult HBV infection in HCV-positive persons  207











Gender (M/F) 15/3 18/16 10/9 0.073
*
Age (yrs) 57±9.3 56±9.4 47±13.7 0.061
†
Anti-HCV (%) 9 (50%) 14 (41%) 9 (47%) 0.808
*
ALT (IU/L) 86±74 93±115 214±466 0.681
†
Statistical significance test was done by Chi-square test
* and Kruskal Wallis test
†.
cAb, anti-HBc (IgG) antibody; sAb, anti-HBs antibody; HCV, hepatitis C virus; ALT, alanine aminotransferase.
In acute hepatitis B, disappearance of HBsAg indicates 
clearance of the virus and, thus, the absence of hepatitis. However, 
even after the disappearance of HBsAg and appearance of 
anti-HBs, low-level viremia may persist.
11 Indeed, HBV DNA 
has been detected in liver tissue after a lapse of several years.
12,13 
Detectable serum HBsAg is absent in around 0.51% of chronic 
HBV carriers
14; however, in most cases HBV DNA is detectable 
in liver tissue even after the disappearance of HBsAg from the 
blood.
15 Thus, the power of an HBsAg test alone to determine 
HBV carrier status is limited.
It remains controversial as to whether HBV occult infection 
has any clinical significance. However, several reports suggest 
the clinical relevance of occult HBV infection: its contagiousness, 
reactivation of occult HBV infection, linkage of occult HBV 
infection to chronic liver diseases and hepatocellular carcinoma 
(HCC), and,
 finally, its potential effect on the progression of liver 
disease.
2
In this study, the frequency of occult HBV infection in the 
liver tissue of anti-HCV positive patients was studied, and the 




This study included 71 subjects with chronic liver disease who 
were HBsAg negative. We performed liver biopsy for the 
diagnosis of underlying liver disease. Of them, 18 were anti- 
HBs-negative and anti-HBc-positive, and 34 were anti-HBc- 
positive and anti-HBs-positive. The remaining 19 were anti-HBc- 
negative, of which 10 were anti-HBs-positive and nine were 
anti-HBs-negative (Table 1). Among the 71 subjects, there were 
32 cases of chronic hepatitis C or HCV-related liver cirrhosis 
(LC) (including seven of HCC), six cases of metastatic liver 
cancer, six cases of alcoholic liver disease, six cases of 
autoimmune hepatitis, six cases of liver abscess, including 
inflammatory pseudotumor, four cases of peripheral cholangio-
carcinoma and three cases of non-alcoholic fatty liver disease. Of 
the remaining eight, two each had primary biliary cirrhosis and 
eosinophilic liver abscess and one each had hemangioma and 
focal nodular hyperplasia. To examine the correlation between 
blood and intrahepatic HBV DNA levels, we measured HBV 
DNA concentrations in liver tissue in six HBsAg-positive cases 
with varying serum HBV DNA concentrations.
Methods
Serum HBsAg and anti-HBc (IgG) was measured using the 
HBsAg Kit
® and the Anti-HBc Kit
® (Beijing North Institute of 
Biological Technology, Beijing, China), and anti-HBs was 
measured by the radioimmunoassay method using the Hepatitis 
B surface antigen 
125I (human subtypes ad and ay) AUSAB
® kit 
(Abbott Laboratories, Abbott Park, IL, USA).
Liver biopsies were conducted using the ACECUT
® Automatic 
Biopsy System (TSK laboratory, Tochigi-Ken, Japan). We used 
an 18-gauge diameter needle and collected 5-mg specimens 
15 mm in length. Biopsies were stored at below -70℃ until 
required. Specimens were sent for histopathological assessment 
by the Pathology Department. Intrahepatic HBV DNA was 
extracted using a QIAamp
® DNA Micro Kit (Qiagen Gmbh, 
Germany). Extracted HBV DNA was quantified by the real-time 
PCR method, using a LightCycler
® instrument (Roche Diagnostics, 
Germany) and RealArt
TM  HBV LC PCR reagent (Artus, 
Germany). According to the manufacturer, the assay detection 
limit was 3.5  IU/mL (18  copies/mL) and its specificity was 
assessed using a panel of 100 HBV-negative serum samples. 
Intrahepatic HBV DNA concentration was expressed as the 
number of viral DNA copies per 1 mg liver tissue. To verify the 
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Figure 1. The overall frequency of detection of intrahepatic HBV 
DNA was 32.4% in all of the specimens and 36.5% in anti-HBc- 
positive subjects. The frequency of intrahepatic HBV DNA detection 
did not differ significantly between the three groups. The frequency 
was highest (50%) in group A, followed by 29.4% in group B and
21.1% in group C. 
*Statistically significant when P<0.05 (Chi-square 
test).
Figure 2. HBV DNA levels were low in all subjects and did not 
differ significantly with anti-HBc or anti-HBs status. 
*Statistically 
significant when P<0.05 (Kruskal-Wallis test).
measured the blood HBV DNA concentration of six HBsAg- 
positive cases using a Cobas Amplicor HBV Monitor
TM kit 
(Roche Molecular Systems, Pleasanton, CA, USA) and examined 
its correlation with the intrahepatic concentration. This study 
was approved by the local Institutional Review Board and was 
conducted in accordance with the principles set forth in the 
Declaration of Helsinki.
We classified pathological findings on chronic hepatitis in 
patients with chronic hepatitis C into minimal, mild, moderate, 
and severe chronic hepatitis, according to Scheuer’s scoring 
system,
16 and assessed the effect of occult HBV infection of 
hepatitis C disease severity.
Statistics
Data are expressed as the mean ± standard deviation, or n (%) 
as appropriate. When comparing the baseline characteristics of 
patients between different groups, chi-square test and Fisher’s 
exact test were used for categorical data, and the Student t test, 
Mann-Whitney U-test and Kruskal-Wallis test were used for 
continuos variables. Spearman’s correlation was used in this 
study. Data were analyzed using the SPSS software (ver. 11.0). 
The base significance level was set at P<0.05.
RESULTS
Detection of intrahepatic HBV DNA according to 
HBV serological status
Intrahepatic HBV DNA was detected in 23 of the 71 (32.4%) 
HBsAg-negative subjects. HBV DNA detection frequency was 
highest (9/18; 50%) in the anti-HBc (+) anti-HBs (-) group, and 
was detected in 10/34 (29.4%) of anti-HBc (+) anti-HBs (+) 
cases. Therefore, intrahepatic HBV DNA was detected in 19/52 
(36.5%) of anti-HBc-positive subjects regardless of anti-HBs 
status (Fig. 1). In the anti-HBc-negative group, intrahepatic 
HBV DNA was detected in 4/19 (21.1%) of subjects. Detection 
frequencies were not significantly different among these groups 
(P=0.149).
Intrahepatic HBV DNA concentrations were 43.6±75.2, 
1044.8±4224.8 and 189.1±511.8 copies/mg in the anti-HBc (+) 
anti-HBs (-), anti-HBc (+) anti-HBs (+) and anti-HBc (-) groups, 
respectively. There was no statistically significant difference 
between them (P=0.442) (Fig. 2).
Detection of intrahepatic HBV DNA according to 
the presence of anti-HCV
Intrahepatic HBV DNA was detected in 9/32 (28.1%) of 
anti-HCV-positive subjects and 14/39 (35.9%) of others, 
suggesting that occult HBV infection was not more common in 
anti-HCV positive patients (Table 2). HCV genotype did not 
affect the detection rate of intrahepatic HBV DNA (Genotype I 
(40%) vs. II (25%) (P=0.656).
Occult HBV infection and liver disease severity 
in anti-HCV positive patients
Intrahepatic HBV DNA was detected in 9 anti-HCV positive 
patients. We divided the 32 anti-HCV-positive individuals into 2 
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Table 2. Characteristics of the patients according to anti-HCV positivity
Anti-HCV positive (n=32) Anti-HCV negative (n=39) P-value
Age (yrs) 53.9±9.5 53.3±12.7 0.842
†
Gender (M/F) 20/12 23/16 0.762
*
ALT (IU/L) 112.1±81.2 132.9±341.4 0.736
†
Anti-HBc positive (%) 23/32 (71.9%) 29/39 (74.4%) 0.814
*
Intrahepatic HBV DNA positive (%) 9/32 (28.1%) 14/39 (35.9%) 0.486
*
Intrahepatic HBV DNA (copies/mg) 714.3±3392 437±2411.3 0.689
†
LC (biopsy proven) 13/32 (40.6%) 6/39 (15.4%) 0.030
*
Statistical significance test was done by Chi-square test
* and t-test
†.
HBV, hepatitis B virus; HCV, hepatitis C virus; ALT; alanine aminotransferase; LC, liver cirrhosis.
 
Figure 3. Histologic grade or stage scores did not differ significantly with HCV status (i.e., HBV DNA-positive vs. 
-negative). 
*Statistically significant when P<0.05 (Chi-square test).
Table 3. Characteristics of anti-HCV-positive subjects according to intrahepatic HBV DNA positivity
HBV DNA-positive (n=9) HBV DNA-negative (n=23) P-value
Gender (M/F) 4/5 16/7 0.240
*
Age (yrs) 55±7.9 53.4±10.2 0.773
†
ALT (IU/L) 85.7±37.6 122.4±91.6 0.651
†
Stage of fibrosis (score) 3.6±0.5 3.2±0.7 0.263
†
Liver cirrhosis (biopsy proven) 5/9 (55.6%) 8/23 (34.8%) 0.427
*
Hepatocellular carcinoma 2/9 (22.2%) 5/23 (21.7%) 1.000
*
Statistical significance test was done by Chi-square test
* and Mann-Whitney U-test
†. 
HBV, hepatitis B virus; ALT, alanine aminotransferase.
compared gender, age, serum ALT, histological activity and the 
frequency of primary liver cancer between the two groups. The 
mean fibrosis score was 3.6 in intrahepatic HBV DNA-positive 
and 3.2 in intrahepatic HBV DNA-negative subjects (P=0.263). 
The frequency of LC and HCC were not significantly different 
between the two groups (LC, P=0.427; HCC, P=1.000) 
(Table 3). 
We compared the hepatic histological activities of the 32 cases 
of chronic hepatitis C according to the detection of intrahepatic 
HBV DNA. When they were divided into mild (1-3 point), 
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Figure 4. Correlation between intrahepatic HBV DNA and serum 
HBV DNA in six HBsAg-positive subjects. 
*Correlation coefficients;
Spearman’s correlation. 
moderate (4-6), and severe (7-9) groups, no significant difference 
was observed in the detection frequency of intrahepatic HBV 
DNA between them (P=0.918). The detection frequency of 
intrahepatic HBV DNA was not different according to the 
fibrosis (P=0.379) (Fig. 3). Gender, age, and serum ALT were 
not significantly different.
Correlation of intrahepatic and serum HBV DNA 
concentrations of HBsAg-positive subjects
We used six HBsAg-positive subjects as positive control. In 
these subjects, blood HBV DNA concentrations varied from 
negative (below 18 copies/mL) to 1.98×10
7 copies/mL. Intra-
hepatic HBV DNA was detected in all six subjects at 
concentrations that varied between 10
5 to 10
9 copies/mg. 
Additionally, intrahepatic HBV DNA concentrations were closely 
correlated with those in blood (r=0.77, P=0.001) (Fig. 4). 
DISCUSSION
The frequency of occult HBV infection may differ geog-
raphically, depending on HBV prevalence. Reported occult HBV 
infection frequencies have been as high as 70-90% of anti- 
HBc-positive individuals in areas of high prevalence but as low 
as 5-20% in areas of low prevalence.
17 A large percentage of 
anti-HBc-positive Koreans are presumed to have been infected. 
However, the prevalence of occult HBV infection was reported 
relatively low (0.7% in HBsAg-negative cases, 1.7% in anti-HBc 
alone positive cases)
18,19 compared to our data. Indeed, in this 
study, intrahepatic HBV DNA was detected in 36.5% of anti- 
HBc-positive cases, showing that occult infection is not rare.
The frequency of occult HBV infection differed according to 
which subjects received the test. It was reported that the 
frequency of occult HBV infection was as high as 30% when the 
subjects were patients with a chronic liver disease of unknown 
cause.
20 This suggests that occult HBV infection alone may 
cause pathological disorders. It is also known that occult HBV 
infection is frequent in those with chronic hepatitis  C. The 
frequency varies from 30 to 50%.
21-24 In another report, HBV 
DNA was detected in 90% of tested liver tissues.
25 This is 
probably because the route of transmission of hepatitis B and C is 
similar. In the present study, intrahepatic HBV DNA was 
detected in 9/32 (28.1%) of anti-HCV-positive and 14/39 (35.9%) 
of anti-HCV-negative subjects. This differs from the previous 
reports. Thus, anti-HCV serum status was apparently not related 
with the presence of occult HBV infection in this study.
Additionally, it has been reported that liver cirrhosis in chronic 
hepatitis C patients is more common in those with occult HBV 
infection
22 and that their serum ALT levels and histological 
activity are high.
24,26 This suggests the possibility that occult 
HBV infection is synergistic with chronic hepatitis C in terms of 
development of liver disease. Moreover, it has been reported that 
in patients with primary liver cancer caused by HCV infection, 
the anti-HBc-positive rate was 69.6%, higher than the 38.2% in 
anti-HBc-negative chronic hepatitis C patients.
27 This suggests 
that if occult HBV infection accompanies chronic hepatitis C 
infection, the risk of liver cancer may increase. These data 
confirm reports that most HBsAg- and anti-HCV-negative 
primary liver cancer patients are anti-HBc-positive
28 and that 
intrahepatic HBV DNA is detected in most of these individuals.
29 
On the other hand, some studies have reported no difference in 
serum ALT levels, histological inflammatory activity, or degree 
of fibrosis between patients with chronic hepatitis C accompanied 
by occult HBV infection and those infected with HCV alone.
29 In 
this study, intrahepatic HBV DNA was detected somewhat more 
frequently in chronic hepatitis C patients with F4 fibrosis, but the 
result was not statistically significant. Furthermore, no significant 
difference was observed in gender, age, serum ALT, degree of 
liver fibrosis, frequency of liver cirrhosis, or primary liver cancer 
whether occult HBV infection was present or not. It will be 
necessary to perform larger studies on the frequency of HBV 
occult infection in chronic hepatitis C patients to determine its 
effect on development of chronic hepatitis C or primary liver 
cancers.
Blood HBV DNA concentration in HBsAg-positive subjects 
was high (10
4 to 10
8 copies/mL), but in those with occult HBV 
infection patients it was below 10
2 copies/mL
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that many occult HBV infection patients would be serum 
PCR-negative. As such, use of liver tissue (as in the present 
study) may be more helpful in detecting occult HBV infection. 
According to one report, intrahepatic HBV DNA was detected in 
37/98 (37.7%) of serum HBV DNA-negative cases by PCR.
30 In 
individuals with occult HBV infection, HBV DNA levels can be 
low even in liver tissue, 0.01-0.1 copy per cell, according to one 
study.
4 Cacciola et al
5 reported average HBV DNA levels of 
34,500 copies per 1  μg DNA extracted from liver tissue in 
patients with active HBV proliferation, but as low as 7,450 and 
224 copies in healthy HBsAg carriers and those with HBV occult 
infection, respectively. This is similar to the data reported here. 
We detected HBV DNA levels of 43.6±75.2, 1044.8±4224.8, 
and 189.1±511.8 copies/mg in the anti-HBc positive/anti-HBs 
negative, anti-HBc positive/anti-HBs positive, and anti-HBc 
negative groups, respectively. Thus, much lower concentrations 
were detected in those with occult HBV infection. On the other 
hand, because viruses may not be distributed evenly in the liver 
of those with occult infection, careful attention is required in 
interpreting PCR-negative results.
7 Additionally, to overcome 
the problem of false positivity, diagnosis of occult infection 
requires a PCR reaction with two primer sets.
7
The reason for the increasing interest in occult HBV infection 
is the increasing evidence of its clinical relevance. This can be 
divided into four categories: contagiousness of occult HBV 
infection, reactivation of occult HBV infection, its link to 
chronic liver diseases, and its link to hepatocellular carcinoma.
2 
It is well-known that HBV infection can be excluded in 
anti-HBc-negative individuals, but in the present study, interestingly, 
intrahepatic HBV DNA was detected in some anti-HBc-negative 
subjects. In such cases, the possibility of false positivity may 
need to be considered, but according to one report,
31 hepatitis 
occurred after transplantation in 50% of patients who received 
livers from anti-HBc-positive donors and as well as in 1.7% of 
patients who received livers from anti-HBc-negative donors. 
Transmission may occur through intraoperative transfusion, but 
this result suggests the possibility that occult HBV infection may 
be present in anti-HBc-negative subjects. Additionally, in 
anti-HBc-negative subjects, intrahepatic HBV DNA has been 
detected in 20% of anti-HCV-positive cases and 12% of 
anti-HCV negative cases.
21 Although it is unclear how anti-HBc 
appears negative in those with HBV infection, it is possible that 
anti-HBc is undetectable due to low serum antibody concentrations 
or that anti-HBc is not produced because HBV core protein is not 
expressed, due to genetic variation.
32 Another possibility is that 
hepatocytes are infected with such a small number of viruses that 
an anti-HBc antibody reaction is not induced.
23
In conclusion, this study found that intrahepatic HBV DNA 
was commonly detectable in HBsAg-negative subjects, and that 
a positive anti-HBc reaction is an important factor related to 
occult HBV infection. However, the frequency of occult HBV 
infection was not affected by chronic hepatitis C infection, and 
the effect of occult HBV infection on the disease severity of 
hepatitis C was not significant.
REFERENCES
1. Mason A, Yoffe B, Noonan C, Mearns M, Campbell C, Kelley A, et al. 
Hepatitis B virus DNA in peripheral-blood mononuclear cells in 
chronic hepatitis B after HBsAg clearance. Hepatology 1992;16:36-41.
2. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B 
virus infection. J Hepatol 2007;46:160-170.
3. Noborg U, Gusdal A, Horal P, Lindh M. Levels of viraemia in subjects 
with serological markers of past or chronic hepatitis B virus infection. 
Scand J Infect Dis 2000;32:249-252.
4. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective 
accumulation of the X transcript of hepatitis B virus in patients negative 
for hepatitis B surface antigen with hepatocellular carcinoma. 
Hepatology 1995;21:313-321.
5. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Villari D, de Franchis 
R, et al. Quantification of intrahepatic hepatitis B virus (HBV) DNA in 
patients with chronic HBV infection. Hepatology 2000;31:507-512.
6. Allain JP. Occult hepatitis B virus infection: implications in transfusion. 
Vox Sang 2004;86:83-91.
7. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. 
Persistent hepatitis B virus infection in subjects without hepatitis B 
surface antigen: clinically significant or purely "occult"? Hepatology 
2001;34:194-203.
8. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J 
Viral Hepat 2002;9:243-257.
9. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 
2002;2:479-486.
10. Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et 
al. Diagnosis and clinical impact of occult hepatitis B infection in 
patients with biopsy proven chronic hepatitis C: a multicenter study. J 
Med Virol 2008;80:1547-1553.
11. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, et al. 
Persistent viremia after recovery from self-limited acute hepatitis B. 
Hepatology 1998;27:1377-1382.
12. Bläckberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute 
self-limited infection persisting for 30 years without sequence variation. 
J Hepatol 2000;33:992-997.
13. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B 
virus persists for decades after patients' recovery from acute viral 
hepatitis despite active maintenance of a cytotoxic T-lymphocyte 
response. Nat Med 1996;2:1104-1108.
14. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants 
and significance of delayed clearance of serum HBsAg in chronic 
hepatitis B virus infection: a prospective study. Hepatology 1991;13: 
627-631.
15. Loriot MA, Marcellin P, Walker F, Boyer N, Degott C, Randria-
natoavina I, et al. Persistence of hepatitis B virus DNA in serum and 
liver from patients with chronic hepatitis B after loss of HBsAg. J 212  The Korean Journal of Hepatology Vol. 17. No. 3, September 2011
Hepatol 1997;27:251-258.
16. Scheuer PJ. Classification of chronic viral hepatitis: a need for 
reassessment. J Hepatol 1991;13:372-374.
17. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden 
menace? Hepatology 2001;34:204-206.
18. Song EY, Yun YM, Park MH, Seo DH. Prevalence of occult hepatitis B 
virus infection in a general adult population in Korea. Intervirology 
2009;52:57-62.
19. Kang SY, Kim MH, Lee WI. The prevalence of "anti-HBc alone" and 
HBV DNA detection among anti-HBc alone in Korea. J Med Virol 
2010;82:1508-1514.
20. Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, et al. 
High incidence of hepatitis B infections among chronic hepatitis cases 
of unknown aetiology. J Hepatol 2001;34:447-454.
21. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, 
Raimondo G. Occult hepatitis B virus infection in patients with chronic 
hepatitis C liver disease. N Engl J Med 1999;341:22-26.
22. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, 
Piccinino F. HCV genotype and "silent" HBV coinfection: two main 
risk factors for a more severe liver disease. J Med Virol 2001;64: 
350-355.
23. Mariscal LF, Rodríguez-Iñigo E, Bartolomé J, Castillo I, Ortiz-Movilla 
N, Navacerrada C, et al. Hepatitis B infection of the liver in chronic 
hepatitis C without detectable hepatitis B virus DNA in serum. J Med 
Virol 2004;73:177-186.
24. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, et 
al. Serologically silent hepatitis B virus coinfection in patients with 
hepatitis C virus-associated chronic liver disease: clinical and virological 
significance. J Med Virol 1999;58:201-207.
25. Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. 
Hepatitis B virus DNA is frequently found in liver biopsy samples from 
hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998; 
54:249-255.
26. Uchida T, Kaneita Y, Gotoh K, Kanagawa H, Kouyama H, Kawanishi T, 
et al. Hepatitis C virus is frequently coinfected with serum 
marker-negative hepatitis B virus: probable replication promotion of the 
former by the latter as demonstrated by in vitro cotransfection. J Med 
Virol 1997;52:399-405.
27. Koike K, Nakamura Y, Kobayashi M, Takada S, Urashima T, Saigo K, et 
al. Hepatitis B virus DNA integration frequently observed in the 
hepatocellular carcinoma DNA of hepatitis C virus-infected patients. 
Int J Oncol 1996;8:781-784.
28. Kim JH, Kim YS, Suh DJ. The prevalence of HBsAg and anti - HCV in 
Korean patients with hepatocellular carcinoma. Korean J Med 1994; 
46:181-190.
29. Kazemi-Shirazi L, Petermann D, Müller C. Hepatitis B virus DNA in 
sera and liver tissue of HBsAg negative patients with chronic hepatitis 
C. J Hepatol 2000;33:785-790. 
30. Mariscal LF, Rodríguez-Iñigo E, Bartolomé J, Castillo I, Ortiz-Movilla 
N, Navacerrada C, et al. Hepatitis B infection of the liver in chronic 
hepatitis C without detectable hepatitis B virus DNA in serum. J Med 
Virol 2004;73:177-186.
31. Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, et 
al. De novo hepatitis B after liver transplantation from hepatitis B core 
antibody-positive donors in an area with high prevalence of anti-HBc 
positivity in the donor population. Liver Transpl 2001;7:51-58.
32. Lok AS. Occult hepatitis B virus infection: diagnosis, implications and 
management? J Gastroenterol Hepatol 2004;19(Suppl):S114-S117.